Physician Perspectives 2017: Treatment Trends in Rheumatoid Arthritis
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› Questions topics:
– JAK inhibitors in RA
– Anti-IL-6 therapies in RA
– Opinions oF JAK inhibitors vs. anti-IL-6 therapies
Scope
› Sociable Pharma conducted an online survey (approx. 60 mins) in September 2017, with 100 specialist rheumatologists
› Physicians interviewed were from 5EU and US countries
› This report contains the findings from the analysis, as well as an overview of the methodology used
Key Highlights
Tofacitinib is expected to remain the leading JAK therapy in the US through 2020 (after which it faces genericization)
Given few discernible differences between sarilumab & tocilizumab with regards to efficacy & safety, differentiation between thetwo therapies will likely relate to physician experience, availability of an autoinjector device (in Europe), and price
JAK inhibitors in Europe are expected to provide (or continue to provide in the US) significant competition to the anti-IL-6 therapies in the monotherapy setting,
Reasons to Buy
Qualitative insight from 100 high-prescribing specialists in RA
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of emerging trends on management of RA
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.